한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제27권1호
  • /
  • Pages.114-119
  • /
  • 2023
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma

  • 투고 : 2022.08.22
  • 심사 : 2022.10.12
  • 발행 : 2023.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

A 51-year-old male patient had four times of massive hematochezia episode three days before arrival. Carbohydrate antigen (CA) 19-9 level was extremely elevated. Computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography identified 5.7 cm sized periampullary duodenal cancer with regional metastatic lymph nodes and vascular invasion to aberrant right hepatic artery, main portal vein, and superior mesenteric vein. Diagnosed as duodenal adenocarcinoma through endoscopic biopsy, 16 times of FOLFIRI (5-fluorouracil, leucovorin, irinotecan) was conducted. The regimen changed to XELOX (capecitabine, oxaliplatine), four times of administration was done, and the CA19-9 level dramatically decreased. The tumor decreased to 2.1 cm. After R0 laparoscopic pylorus preserving pancreatoduodenectomy, no adjuvant therapy was given. No sign of recurrence or metastasis was reported, and the patient reached complete remission after five years. We reported a case where neoadjuvant chemotherapy for locally advanced duodenal adenocarcinoma was shown to be effective.

키워드

참고문헌

  1. Sabiston DC, Townsend CM. Sabiston textbook of surgery: the biological basis of modern surgical practice. 19th ed. Philadelphia: Elsevier Saunders, 2012. 
  2. Hong S, Won YJ, Lee JJ, Jung KW, Kong HJ, Im JS, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat 2021;53:301-315.  https://doi.org/10.4143/crt.2021.291
  3. Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 2000;135:635-641; discussion 641-642.  https://doi.org/10.1001/archsurg.135.6.635
  4. Kelsey CR, Nelson JW, Willett CG, Chino JP, Clough RW, Bendell JC, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1436-1441.  https://doi.org/10.1016/j.ijrobp.2007.05.006
  5. Onkendi EO, Boostrom SY, Sarr MG, Farnell MB, Nagorney DM, Donohue JH, et al. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg 2012;16:320-324.  https://doi.org/10.1007/s11605-011-1667-7
  6. Ji X, Bu ZD, Yan Y, Li ZY, Wu AW, Zhang LH, et al. The 8th edition of the American Joint Committee on Cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. Gastric Cancer 2018;21:643-652.  https://doi.org/10.1007/s10120-017-0779-5
  7. Dave A, Wiseman JT, Cloyd JM. Duodenal adenocarcinoma: neoadjuvant and adjuvant therapy strategies. Expert Opin Orphan Drugs 2019;7:463-472.  https://doi.org/10.1080/21678707.2019.1684257
  8. Ryder NM, Ko CY, Hines OJ, Gloor B, Reber HA. Primary duodenal adenocarcinoma: a 40-year experience. Arch Surg 2000;135:1070-1074; discussion 1074-1075.  https://doi.org/10.1001/archsurg.135.9.1070
  9. Dave A, Wiseman JT, Cloyd JM. Duodenal adenocarcinoma: more questions than answers. Laparosc Surg 2018;2:5. 
  10. Cloyd JM, George E, Visser BC. Duodenal adenocarcinoma: advances in diagnosis and surgical management. World J Gastrointest Surg 2016;8:212-221.  https://doi.org/10.4240/wjgs.v8.i3.212
  11. NCCN. Clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 1.2022 [Internet]. Plymouth Meeting: NCCN 2022 [cited 2022 June 8]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. 
  12. Velandia C, Morales RD, Coello C, Mendoza AG, Perez G, Aguero E. Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. Ecancermedicalscience 2018;12:816. 
  13. Zhang GY, Mao J, Zhao B, Long B, Zhan H, Zhang JQ, et al. Duodenal bulb adenocarcinoma benefitted from neoadjuvant chemotherapy: a case report. Chemotherapy 2017;62:290-294.  https://doi.org/10.1159/000469700
  14. Kaslow SR, Prendergast K, Vitiello GA, Hani L, Berman RS, Lee AY, et al. Systemic therapy for duodenal adenocarcinoma: an analysis of the National Cancer Database (NCDB). Surgery 2022;172:358-364.  https://doi.org/10.1016/j.surg.2022.03.009
  15. Van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 2022;160:140-149.  https://doi.org/10.1016/j.ejca.2021.10.023
  16. Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220-1230.  https://doi.org/10.1200/JCO.21.02233
  17. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1020-1027. https://doi.org/10.1001/jamaoncol.2019.0892